Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. On December 24, 2018, Junshi Biosciences was listed on the Main Board of the Stock Exchange of Hong Kong with the stock code: 1877.HK. On July 15, 2020, the Company was listed on the STAR Market of the Shanghai Stock Exchange with the stock code: 688180.SH.
Junshi Biosciences has established a diversified R&D pipeline comprising 28innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurologic, and infectious diseases. The Company was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China and clinical trial application approval for anti-PCSK9 monoclonal antibody from NMPA. The world's first in human anti-BTLA antibody for solid tumors was officially approved for clinical trials by the FDA and the NMPA. From this year onwards, Junshi Biosciences pooled its efforts with Chinese science institutions to co-develop JS016, China's first neutralizing human monoclonal antibodies against SARS-CoV-2, that has entered Phase Ib/II clinical trials, part of our continuous innovation for disease control and prevention in China and beyond.
Junshi Biosciences has independently developed and established an integrated technology system covering the entire lifecycle of protein drugs from early R&D to industrialization. The system involves seven technology platforms, which are (i)automated high-efficiency screening platform for antibody selection and functional assays, (ii)high-yielding stable expression cell lines screening and establishment platform, (iii) antibody humanization and construction platform, (iv)CHO cell fermentation process development platform, (v)antibody purification process development and formulation optimization platform, (vi)human transmembrane receptor protein array and high-throughput screening platform and (vii)antibody quality research, control and assurance platform. Meanwhile, a globally integrated R&D process has been established. With four R&D centers worldwide, the Company has outstanding ability to discover and develop innovative biologics drugs, including key steps, i.e. independent target assessment, mechanism study and validation, clinical drug screening and functional validation, etc. In regard to production, the Company has two monoclonal antibody production bases with combined 33,000L fermentation capacity in China, located in Suzhou Wujiang and Shanghai Lingang. The two established manufacturing infrastructures can support commercialization and provide our partners and patients with high quality products through a global supply chain network.
|Earnings Per Share||-2.03||-0.96||-1.21|
|R&D expenditure as a % of operating revenue||112.72%||122.06%||18,383.07%|
|Total Owners' Equity||5,827.81||2,978.03||3,314.14|
|Net Cash Flows-Operating||-1,456.38||-1,179.48||-516.95|
|Net Cash Flows-Investing||-740.41||-959.59||-414.79|
|Net Cash Flows-Financing||4,413.52||593.58||3,432.60|
|Name||No. of Shares Held (mn)||% of Shares Held|
|HKSCC NOMINEES LIMITED||182.74||20.94%|
|Shanghai Tanying Investment Partnership （LP)（上海檀英投资合伙企业（有限合伙））||76.59||8.78%|
|Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)（苏州瑞源盛本生物医药管理合伙企业（有限合伙））||43.58||5.00%|
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.